Opus Genetics, Inc. (IRD) Key Metrics
IRD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $319.5M
- Enterprise value
- $347.6M
- P/E (TTM)
- —
- Forward P/E
- 12.0
- PEG ratio
- —
- Price / sales
- 32.4 10-yr median 2.9
- Price / book
- 23.8 10-yr median 1.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.62
IRD key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIRD returns How much profit the business earns on the capital it uses.
IRD financial health Debt, liquidity and how easily interest is covered.
IRD efficiency & capital use Working capital cycle and where the cash goes.
IRD valuation history
IRD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IRD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IRD cash returned to shareholders
IRD price vs earnings per share
IRD key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | — | $31.8M | $65.0M | $72.7M | — | — | — |
| Enterprise value | — | $20.3M | $14.5M | $30.0M | — | — | — |
| P/E ratio | — | — | — | 4.1 | — | — | — |
| Price / sales | — | 2.9 | 3.4 | 1.8 | — | — | — |
| Price / book | — | 4.7 | 1.3 | 1.6 | — | — | — |
| Price / free cash flow | — | — | — | 5.1 | — | — | — |
| Price / operating cash flow | — | — | — | 5.1 | — | — | — |
| EV / sales | — | 1.8 | 0.8 | 0.8 | — | — | — |
| EV / EBITDA | — | — | — | 1.6 | — | — | — |
| EV / free cash flow | — | — | — | 2.1 | — | — | — |
| Earnings yield | — | −181.0% | −15.4% | 24.6% | — | — | — |
| Free cash flow yield | — | −80.4% | −1.7% | 19.7% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.2% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $2.01 | $1.19 | $3.01 | $3.53 | $3.73 | $6.49 | $7.64 |
| Per share | |||||||
| Revenue per share | — | $0.41 | $0.88 | $1.93 | — | — | — |
| Earnings per share | — | −$2.15 | −$0.46 | $0.87 | — | — | — |
| Operating cash flow per share | — | −$0.96 | −$0.05 | $0.69 | — | — | — |
| Free cash flow per share | — | −$0.96 | −$0.05 | $0.69 | — | — | — |
| Cash per share | — | $1.14 | $2.34 | $2.07 | — | — | — |
| Book value per share | — | $0.25 | $2.31 | $2.24 | — | — | — |
| Tangible book value per share | — | $0.25 | $2.31 | $2.24 | — | — | — |
| Capex per share | — | $0.00 | $0.00 | $0.00 | — | — | — |
| Debt per share | — | $0.71 | — | — | — | — | — |
| Shares outstanding | — | 26.7M | 21.6M | 20.6M | — | — | — |
| Change in shares outstanding | — | +23.7% | +4.8% | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −449.4% | −203.2% | −20.8% | 52.3% | — | — | — |
| Return on assets (ROA) | −113.9% | −126.7% | −19.4% | 47.7% | −259.1% | −253.0% | −345.8% |
| Return on tangible assets | −98.7% | −156.1% | −18.5% | 36.5% | −217.4% | −139.2% | −345.8% |
| Free cash flow margin | −248.3% | −232.7% | −5.8% | 35.9% | — | — | — |
| Income quality (OCF / net income) | — | — | — | 0.80 | — | — | — |
| Financial health | |||||||
| Total debt | $1.1M | $18.8M | — | — | $538,000 | — | $5.7M |
| Cash & short-term investments | $45.1M | $30.3M | $50.5M | $42.7M | $24.8M | $16.4M | $1.5M |
| Net debt | −$44.0M | −$11.5M | −$50.5M | −$42.7M | −$24.2M | −$16.4M | $4.1M |
| Debt / equity | 0.07 | 2.80 | — | — | 0.02 | — | — |
| Debt / assets | 0.02 | 0.51 | — | — | 0.02 | — | 3.18 |
| Net debt / EBITDA | — | — | — | −2.34 | — | — | — |
| Current ratio | 6.43 | 3.24 | 13.35 | 17.79 | 6.76 | 5.55 | 0.19 |
| Quick ratio | 6.43 | 3.24 | 13.35 | 17.79 | 6.76 | 5.55 | 0.19 |
| Interest coverage | -26.3 | — | -8.0 | — | — | -2.9 | -3.0 |
| Working capital | $42.3M | $25.3M | $49.9M | $46.2M | $22.2M | $14.5M | −$7.6M |
| Invested capital | −$28.6M | −$4.8M | −$610,000 | $3.6M | −$2.0M | −$29.9M | −$3.4M |
| Tangible asset value | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M | −$13.5M | −$7.6M |
| Net current asset value | $15.1M | $6.5M | $49.9M | $46.2M | $22.2M | −$13.5M | −$7.6M |
| Graham number | — | — | — | $6.62 | — | — | — |
| Graham net-net per share | — | $0.17 | $2.23 | $2.12 | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | $152,000 | $79,000 | $0 | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Capex / operating cash flow | — | — | — | 0.0% | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.33 |
| Stock-based compensation / revenue | 23.9% | 30.6% | 18.4% | 4.5% | 325.0% | — | — |
| R&D / revenue | 217.0% | 244.3% | 92.7% | 36.0% | 2,576.1% | — | — |
| SG&A / revenue | 154.9% | 165.7% | 62.8% | 18.2% | 1,378.8% | — | — |
| Efficiency | |||||||
| Days sales outstanding | 114.9 | 134.6 | 68.8 | 22.2 | 0.0 | — | — |
| Days payables outstanding | 22,178.9 | 96,743.2 | 98,002.5 | 121,043.1 | 127,658.8 | 35,496.2 | — |
| Cash conversion cycle (days) | -22,064.0 | -96,608.7 | -97,933.7 | -121,020.9 | -127,658.8 | — | — |
| Receivables turnover | 3.18 | 2.71 | 5.30 | 16.43 | — | — | 0.00 |
| Payables turnover | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — |
| Asset turnover | 0.33 | 0.24 | 0.37 | 1.06 | 0.03 | 0.00 | 0.00 |
| Average receivables | $4.5M | $4.1M | $3.6M | $2.4M | $0 | — | $125,000 |
| Average payables | $3.2M | $2.7M | $1.6M | $1.3M | $1.4M | $778,000 | $342,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from IRD's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IRD valuation and financial ratios
Opus Genetics earned a return on equity of −449.4% in fiscal 2025. It ended the year with $1.1 million of debt and $45.1 million in cash and short-term investments, a net cash position of $44.0 million. It returned $0.2 million to shareholders: $0 in dividends and $0.2 million in share buybacks.
See the IRD income statement, the IRD chart for price history, or the IRD stock overview for the latest quote and news.
IRD key metrics FAQ
What is Opus Genetics's return on equity?
Opus Genetics's return on equity (ROE) was −449.4% in fiscal 2025: net income of -$49.6 million on average shareholders' equity of $11.0 million.
How much debt does Opus Genetics have?
Opus Genetics had total debt of $1.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
Does Opus Genetics buy back its shares?
Yes. Opus Genetics spent $0.2 million on net share repurchases in fiscal 2025.
What is Opus Genetics's current ratio?
Opus Genetics's current ratio was 6.43 at the end of fiscal 2025: current assets were 6.43 times current liabilities.